Type 2 Diabetes (T2D) Clinical Trials

• Signed informed consent in a language understandable to the participant prior to any study-mandated procedure.

• Healthy male (Parts A and B) or female (Part B) aged between 18 and 65 years (inclusive) at screening or, male or female with cardiovascular risk factors between 18 and 75 years (inclusive) (Part C).

• For Parts A and B: Body mass index of 18.0 to 29.9 kg/m2 (inclusive) at screening.

• For Part C: Presence of either obesity (defined as a BMI of 30.0-42.0 kg/m2 inclusive) and/or existing diagnosis of well controlled type II diabetes (with HbA1c \>6.5% or 48 mmol/mol and ≤8.5% or 69 mmol/mol) (for participants with diabetes the BMI can range between 18.0-42.0 kg/m2 inclusive).

• For Part C: serum CRP \>3.0 mg/L and \<10.0 mg/L at screening and reconfirmed prior first dosing.

• Ability to communicate well with the investigator, and to understand and comply with the study requirements.

• Systolic blood pressure (SBP) 90-140 mmHg, diastolic blood pressure (DBP) 45-90 mmHg, and pulse rate 40 to 100 beats per minute (bpm) (all inclusive), measured on either arm (same arm used for both screening and admission), after 5 min in the supine position at screening and admission. For Part C: SBP may be 90-160 mmHg, and DBP 45-100 mmHg (all inclusive).

• 12-lead safety ECG: QT interval corrected for HR using Fridericia's formula (QTcF) \<450 ms for male participants and \<470 ms for female participants, QRS interval \<120 ms, PR interval \<220 ms, and HR 40 to 100 bpm (inclusive), and without clinically relevant abnormalities, measured after 5 min in the supine position at screening and admission.

• For Part C: Estimated glomerular filtration rate (eGFR) \>60 mL/min/1.73 m2

⁃ Fertile male participants (defined as physiologically capable of conceiving a child according to the investigator's judgment) must agree to refrain from fathering a child and:

∙ Be sexually abstinent with women of childbearing potential (WoCBP) or use condoms during sexual intercourse with WoCBP from (first) study treatment administration up to at least 90 days after (last) study treatment administration. Male participants must advise their WoCBP partners consistently to use a highly effective method of contraception with a failure rate of \<1% per year.

‣ Do not donate sperm from (first) study treatment administration up to at least 90 days after (last) study treatment administration.

⁃ Parts B and C only: Female participants must have a negative serum pregnancy test at screening and a negative urine pregnancy test at admission and a follicle-stimulating hormone (FSH) test must be performed at screening. WoCBP must agree to consistently and correctly use (from screening, during the entire study, and for at least 30 days after the last study treatment administration) a highly effective method of contraception with a failure rate of \<1% per year, be sexually inactive, or have a vasectomized partner with a post-vasectomy semen analysis negative for sperm at least 6 months before screening. If a hormonal contraceptive is used, it must be initiated at least 1 month before the first study treatment administration and should be used in conjunction with barrier methods. WoCBP must agree to not donate eggs from screening until at least 30 days after the last study treatment administration.

⁃ Parts B and C only: WoNCBP must be postmenopausal or have documented previous bilateral salpingectomy, bilateral salpingo-oophorectomy or hysterectomy, or with premature ovarian failure (confirmed by a specialist), XY genotype, uterine agenesis.